Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02005289
Title Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

prolymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

Therapies

Lenalidomide + Tafasitamab-cxix

Ibrutinib + Tafasitamab-cxix

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.